CogState (CGS.AX) Akcie Kurz
CogState Kurz
Za posledních 19 let vzrostly tržby CogState o 20,0 % ročně a dosáhly 53,09 Mil. USD. Zisk na akcii rostl o 8,5 % ročně za posledních 16 let. U CogState je čistá marže 19,1 % nahoru oproti 16,0 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 1,21 %. Výplatní poměr je kolem 34 % zisku. Konsenzuální 12měsíční cílová cena pro CogState je 2,15 USD, asi pod cenu o 9,0 %. Z 6 analytiků jich 5 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie CogState
Obchodní model CogState a analýza akcií
Nejčastější otázky týkající se akcie CogState
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analytici aktuálně stanovují průměrnou cílovou cenu 2,15 USD pro akcii CogState (medián: 2,15 USD), tedy -9,0 % vůči poslední ceně. Konsensus vychází z 6 hodnocení analytiků.
7 analytiků aktuálně hodnotí akcii CogState: 6 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u CogState tržby 128,65 Mil. USD a zisk na akcii 0,09 USD.
Při aktuálním kurzu se akcie CogState obchoduje za 2,10 EUR (2,36 USD).
Akcie CogState (CGS.AX) je kótována na 2 burzách, mimo jiné: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
Tržby očekávané za CogState činí 128,65 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za CogState činí 16,22 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) CogState je aktuálně 25,31. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie CogState.
Poměr ceny k tržbám (P/S) CogState je aktuálně 3,19. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie CogState.
Score kvality pro CogState je 6/10.
ISIN CogState je AU000000CGS8. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
Ticker CogState je CGS.AX. Symbol tickeru se používá k obchodování akcií CogState na burze.
CogState akcie
CogState Peer Group
CogState Ticker
CogState FIGI
Všechny fundamentální údaje o CogState v podrobné analýze
Naše analýzy akcií společnosti CogState zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti CogState. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: